Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.

Trial Profile

Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRE-3
  • Most Recent Events

    • 20 Jan 2018 Results assessing impact of Tfh cell/ B cell pathway-related genetic variants from FIRE-3 and TRIBE studies presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Results (n=451) assessing impact of single nucleotide polymorphisms (SNPs) in beta-defensin pathways by taking patient data from FIRE-3 and TRIBE studies, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results (n=451) assessing whether single-nucleotide polymorphisms in cancer-associated fibroblasts (CAFs) related genes predict clinical outcomes in metastatic colorectal cancer patients by taking data from TRIBE and FIRE-3 trials, presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top